Press releases
2024
6 Jan 2024, 14:00 | Regulatory
· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SR…
2023
14 Dec 2023, 20:00 | Regulatory
Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared to standard of care
13 Dec 2023, 07:00 | Regulatory
7 Dec 2023, 07:00
5 Dec 2023, 13:05 | Regulatory
27 Nov 2023, 07:00 | Regulatory
26 Oct 2023, 07:00 | Regulatory
• Encouraging high-level results for first-in-human trial of HNSA-5487
• Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences
• Dr. Hitto Kaufmann appointed new CSO
• Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences
• Dr. Hitto Kaufmann appointed new CSO